FEIBA VH

Anti-Inhibitor Coagulant Complex

Vapor Heated

DESCRIPTION
FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated, is a freeze-dried sterile human plasma fraction with Factor VIII inhibitor bypassing activity. In vitro, FEIBA VH shortens the activated partial thromboplastin time (APTT) of plasma containing Factor VIII inhibitor. Factor VIII inhibitor bypassing activity is expressed in arbitrary units. One IMMUNO Unit of activity is defined as that amount of FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated which shortens the APTT of a high titer Factor VIII inhibitor reference plasma to 50% of the blank value. The product is intended for intravenous administration.

FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated contains Factors II, IX, and X, mainly non-activated, and Factor VII in a maining the activated form. The product contains approximately equal units of Factor VIII inhibitor bypassing activity and Prothrombin Complex Factors. In addition, 1–6 units of Factor VIII coagulant antigen (FVIII C:Ag) per mL are present. The preparation contains only traces of factors of the kinin generating system. It contains no heparin.

Reconstituted FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated contains 4 mg of triisodium citrate and 8 mg of sodium chloride per mL.

FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated has been prepared from Source Plasma and/or Plasma.

The product has been subjected to in-process virus inactivation where vapor is first applied for 10 hours at 60° ± 0.5°C and an excess pressure of 370 ± 30 mbar. (Refer to Clinical Pharmacology and Warnings sections.)

CLINICAL PHARMACOLOGY

In a preclinical study to determine the virus inactivating efficacy of vapor heating, samples of bulk FEIBA Immuno Anti-Inhibitor Coagulant Complex, were spiked with 2 x 10⁹/mL infectious units of HIV and subjected to vapor heat treatment. The residual virus titer was found to be less than 1 infectious unit/0.5 mL. A clinical study/ testing Anithemophilic Factor treated by a similar vapor heating procedure has shown none of 4 lots used in the study to produce non, nonB hepatitis in intensively followed patients naive to blood product administration.

The safety and efficacy of FEIBA Immuno Anti-Inhibitor Coagulant Complex, has been demonstrated by two prospective clinical trials1. The first, conducted by Saxma and collaborators during 1979 and early 1980, was a randomized double-blind study comparing the effect of FEIBA Immuno, Anti-Inhibitor Coagulant Complex, and PROTHROMPLEX IMMUNO (a non-activated prothrombin complex concentrate) in 15 patients with hemophilia A and inhibitors to Factor VIII. A total of 50 bleeding episodes (primarily joint and musculoskeletal plus a few mucocutaneous) were treated. A single dose of 88 Units per kg of body weight was used uniformly for treatments with FEIBA Immuno, Anti-Inhibitor Coagulant Complex. The study showed that, based on subjective patient evaluation, FEIBA Immuno was fully effective in 41.0% and partly effective in 24.6% of episodes (i.e. combined effectiveness of 65.6%), while PROTHROMPLEX IMMUNO was rated fully effective in 25.0% and partly effective in 21.4% of episodes (i.e. combined effectiveness of 46.4%).

The second study with FEIBA Immuno, Anti-Inhibitor Coagulant Complex, was a multiclinic study conducted by Hilgarten et al. It was designed to evaluate the efficacy of FEIBA Immuno, Anti-Inhibitor Coagulant Complex in the treatment of joint, mucous membrane, mucocutaneous, and emergency bleeding episodes such as central nervous system hemorrhages and surgical bleedings. In 49 patients with inhibitor titers greater than or equal to 5 Bethesda Units (from nine co-operating hemophilia centers), 489 single doses were given for the treatment of 165 bleeding episodes. The usual dosage was 50 Units per kg of body weight, repeated at 12-hour intervals (6-hour intervals in mucous membrane bleedings), if necessary. Bleeding was controlled in 153 episodes (93%). In 130 (78%) of the episodes, hemostasis was achieved with one or more infusions within 36 hours. Of these 36% were controlled with one infusion within 12 hours. An additional 14% of episodes responded after more than 36 hours. Of the 489 single doses only 18 (3.7%) caused minor transient reactions in recipients. 10 out of 49 patients (20%) showed a rise in their inhibitor titer. In 5 of these patients (10%) the rise was tenfold or more. However, of these 10 patients 3 had received Factor VIII or Factor IX concentrates within 2 weeks prior to treatment with FEIBA Immuno, Anti-Inhibitor Coagulant Complex. These anamnestic rises have not been observed to interfere with the efficacy of FEIBA Immuno, Anti-Inhibitor Coagulant Complex.

INDICATIONS AND USAGE
FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated is intended for the control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and B patients with inhibitors.

In addition, the use of FEIBA Immuno, Anti-Inhibitor Coagulant Complex, has been described in a few non-hemophiliacs with acquired inhibitors to Factors VIII, XI, and XII1. One case has been reported where FEIBA Immuno, Anti-Inhibitor Coagulant Complex, was effective in a patient with von Willebrand’s disease with an inhibitor.

Clinical experience suggests that patients with a Factor VIII inhibitor titer of less than 5 B.U. may be successfully treated with Antihemophilic Factor. Patients with titers ranging between 5 and 10 B.U. may either be treated with Antihemophilic Factor or FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated. Cases with Factor VIII inhibitor titers greater than 10 B.U. have generally been refractory to treatment with Antihemophilic Factor.

Guidelines to First and Second Choice Treatment:

<table>
<thead>
<tr>
<th>Patient’s Inhibitor</th>
<th>Clinical Situation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titer</td>
<td>Minor Bleeding</td>
</tr>
<tr>
<td>less than 5 B.U.</td>
<td>AHF</td>
</tr>
<tr>
<td>5 to 10 B.U.</td>
<td>AHF</td>
</tr>
<tr>
<td>more than 10 B.U.</td>
<td>AICC</td>
</tr>
</tbody>
</table>

Inadequate response to treatment may result from an abnormal platelet count or impaired platelet function

which were present before treatment with FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated.

CONTRAINdications

The use of FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated is contraindicated in patients who are known to have a normal coagulation mechanism.

WARNINGS
FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated, is made from human plasma. Products made from plasma may contain infectious agents, such as viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by effective manufacturing screening, testing for the presence of certain current virus infections, by inactivating and/or removing certain viruses. Despite these measures, such products can still potentially transmit disease. Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically the Creutzfeldt-Jacob disease (CJD) agent. ALL infections thought to have been transmitted by this product should be reported by the physician or other health care provider to Baxter Healthcare Corporation, at 1-800-423-2982 (in the U.S.). The physician should discuss the risks and benefits of this product with the patient.

FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated must be used only in patients with circulating inhibitors to one or more coagulation factors and should not be used for the treatment of bleeding episodes resulting from coagulation factor deficiencies. It should not be given to patients with significant signs of disseminated intravascular coagulation (DIC) or fibrinolysis.

In the course of treatment with preparations containing the prothrombin complex thromboembolic events may occur, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Single doses of 100 units per kg of body weight of FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated and daily doses of 200 units per kg of body weight of FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated should not be exceeded. Patients receiving more than 100 units per kg of body weight of FEIBA VH Anti-Inhibitor Coagulant Complex, Vapor Heated must be monitored for the development of DIC and/or symptoms of acute coronary ischemia (see Adverse Reactions section).

High doses of FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated should be given only as long as absolutely necessary to stop bleeding.

It has been reported that FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated and antiﬁbrinolytics have been given simultaneously without complications. It is, however, recommended not to use antiﬁbrinolytics until 12 hours after the administration of FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated.

Anamnestic responses with rise in Factor VIII inhibitor titer have been observed in 20% of the cases (see Clinical Pharmacology section). Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly nonA, nonB hepatitis.

PRECAUTIONS

Monitoring of Therapy
If clinical signs of intravascular coagulation occur, which include changes in blood pressure, pulse rate, respiratory distress, chest pain and cough, the infusion should be stopped promptly and appropriate diagnostic and therapeutic measures are to be initiated.

Laboratory indications of DIC are decreased fibrinogen, decreased platelet count, and/or presence of fibrin-fibrinogen degradation products (FDP). Other indications of DIC include significantly prolonged thrombin time, prothrombin time, or partial thromboplastin time.

Information for Patients
Some viruses, such as parvovirus B19 or hepatitis A, are particularly difficult to remove or inactivate at this time. Parvovirus B19 most seriously affects pregnant women or immune-compromised individuals. Symptoms of parvovirus B19 infection include fever, drowsiness, chills, and runny nose followed about two weeks later by a rash, and joint pain. Evidence of hepatitis A may include several days to weeks of poor appetite, tiredness, and low-grade fever followed by nausea, vomiting, and pain in the belly. Dark urine and a yellowed complexion are also common symptoms. Patients should be encouraged to consult their physician if such symptoms appear.

Non Hemophilic Patients
Non hemophilic patients with acquired inhibitors against Factors VIII, IX or XI may have both a bleeding tendency and an increased risk of thrombosis at the same time.

Laboratory Tests and Clinical Efficacy
Tests used to control efficacy such as APTT, WBCT, and TEG do not correlate with clinical improvement. For this reason, attempts at normalizing these values by increasing the dose of FEIBA VH, Anti-Inhibitor Coagulant
In a patient with a body
following four indications, all of which have undergone careful clinical evaluation:

3. Remove and discard the filter needle. Attach a suitable intravenous needle or infusion set with winged adapter, and inject solution intravenously.

2. Inject air and withdraw solution into the syringe.

Avoid freezing, which may damage the diluent bottle.

FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated is supplied as freeze-dried powder, accompanied by a suitable volume of Sterile Water for Injection, U.S.P. (This Product Contains Dry Natural Rubber.), a sterile
tubing assembly, and a sterile double-ended needle.

For Intravenous Infusion

A dose of 50 units per kg of body weight is recommended to be given at 6-hour intervals under careful monitoring (visible bleeding site, repeated measurements of the patient’s hematocrit). Again, if hemorrhage does
not stop, the dose may be increased to 100 units per kg of body weight at 6-hour intervals. However, 2 such administrations or 200 units per kg of body weight a day should not be exceeded.

Soft Tissue Hemorrhage

For serious soft tissue bleeding, such as retroperitoneal bleeding, doses of 100 units per kg of body weight at 12-hour intervals are recommended. A daily dosage of 200 units per kg of body weight should not be exceeded.

Other Severe Hemorrhages

Severe hemorrhages, such as CNS bleedings have been effectively treated with doses of 100 units per kg of body weight at 12-hour intervals. Sometimes, FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated may be indicated at 6-hour intervals until clear clinical improvement is achieved.

Reconstitution

Do not refrigerate after reconstitution!

After complete reconstitution of FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated, its injection or infusion should be commenced as promptly as practicable, but must be completed within three hours following reconstitution.

The solution must be given by intravenous injection or intravenous drip infusion and the
maximum injection or infusion rate must not exceed 2 units per kg body weight per minute. In a patient with a body weight of 75 kg, this corresponds to an infusion rate of 2.5-7.5 mL per minute depending on the number of units per vial (see label on vial).

For Intravenous Injection

1. After reconstituting the concentrate as described under Reconstitution, attach the enclosed filter needle to a sterile disposable syringe. Insert filter needle through the concentrate bottle stopper.

2. Inject air and withdraw solution into the syringe.

3. Remove and discard the filter needle. Attach a suitable intravenous needle or infusion set with winged adapter, and inject solution intravenously.

For Intravenous Infusion

Prepare a solution of FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated as described under Reconstitution.

Follow manufacturer’s instructions for the administration set used. Make sure that the set contains an adequate filter.

HOW SUPPLIED

FEIBA VH, Anti-Inhibitor Coagulant Complex, Vapor Heated is supplied as freeze-dried powder, accompanied by a suitable volume of Sterile Water for Injection, U.S.P. (This Product Contains Dry Natural Rubber), a sterile double-ended needle, and a sterile filter needle.

The number of Units of Factor VIII inhibitor bypassing activity is stated on the label of each bottle.

STORAGE

Store at refrigerated temperature (2° to 8°C, 35° to 46°F). Avoid freezing, which may damage the diluent bottle.

REFERENCES


4. Mannucci P. M.: Personal communication


To enroll in the confidential, Industry-wide Patient Notification System, call 1-888-UPDATE U (1-888-873-2838)

FEIBA, FEIBA Immuno and Prothromplex Immuno are trademarks of Baxter AG, Vienna, Austria. Baxter is a trademark of Baxter International, Inc., registered in the U.S. Patent and Trademark Office

Baxter Healthcare Corporation

Glendale, CA 91203 USA

U.S. License No. 140

U.S. Pat. Nos. 4,395,396, and 4,640,834

©2000 Baxter AG

All Rights Reserved

Revised September 2001

6205820EH16